Cargando…

Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer

BACKGROUND: The lack of non-invasive methods for detection of early micro-metastasis is a major cause of the poor prognosis of non-small cell lung cancer (NSCLC) brain metastasis (BM) patients. Herein, we aimed to identify circulating biomarkers based on proteomics for the early diagnosis and monito...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Song, Liu, Wenwen, Xu, Mingxin, Qin, Huamin, Liu, Chang, Zhang, Rui, Zhou, Sihai, Li, Encheng, Liu, Zhiyu, Wang, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174239/
https://www.ncbi.nlm.nih.gov/pubmed/35217799
http://dx.doi.org/10.1038/s41416-022-01744-3
_version_ 1784722196323631104
author Wei, Song
Liu, Wenwen
Xu, Mingxin
Qin, Huamin
Liu, Chang
Zhang, Rui
Zhou, Sihai
Li, Encheng
Liu, Zhiyu
Wang, Qi
author_facet Wei, Song
Liu, Wenwen
Xu, Mingxin
Qin, Huamin
Liu, Chang
Zhang, Rui
Zhou, Sihai
Li, Encheng
Liu, Zhiyu
Wang, Qi
author_sort Wei, Song
collection PubMed
description BACKGROUND: The lack of non-invasive methods for detection of early micro-metastasis is a major cause of the poor prognosis of non-small cell lung cancer (NSCLC) brain metastasis (BM) patients. Herein, we aimed to identify circulating biomarkers based on proteomics for the early diagnosis and monitoring of patients with NSCLC BM. METHODS: Upregulated proteins were detected by secretory proteomics in the animal-derived high brain metastatic lung cancer cell line. A well-designed study composed of three independent cohorts was then performed to verify these blood-based protein biomarkers: the serum discovery and verification cohorts (n = 80; n = 459), and the tissue verification cohort (n = 76). Logistic regression was used to develop a diagnostic biomarker panel. Model validation cohort (n = 160) was used to verify the stability of the constructed predictive model. Changes in serum Cathepsin F (CTSF) levels of patients were tracked to monitor the treatment response. Progression-free survival (PFS) and overall survival (OS) were analysed to assess their prognostic relevance. RESULTS: CTSF and Fibulin-1 (FBLN1) levels were specifically upregulated in sera and tissues of patients with NSCLC BM compared with NSCLC without BM and primary brain tumour. The combined diagnostic performance of CTSF and FBLN1 was superior to their individual ones. CTSF serum changes were found to reflect the therapeutic response of patients with NSCLC BM and the trends of progression were detected earlier than the magnetic resonance imaging changes. Elevated expression of CTSF in NSCLC BM tissues was associated with poor PFS, and was found to be an independent prognostic factor. CONCLUSIONS: We report a novel blood-based biomarker panel for early diagnosis, monitoring of therapeutic response, and prognostic evaluation of patients with NSCLC BM.
format Online
Article
Text
id pubmed-9174239
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91742392022-06-09 Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer Wei, Song Liu, Wenwen Xu, Mingxin Qin, Huamin Liu, Chang Zhang, Rui Zhou, Sihai Li, Encheng Liu, Zhiyu Wang, Qi Br J Cancer Article BACKGROUND: The lack of non-invasive methods for detection of early micro-metastasis is a major cause of the poor prognosis of non-small cell lung cancer (NSCLC) brain metastasis (BM) patients. Herein, we aimed to identify circulating biomarkers based on proteomics for the early diagnosis and monitoring of patients with NSCLC BM. METHODS: Upregulated proteins were detected by secretory proteomics in the animal-derived high brain metastatic lung cancer cell line. A well-designed study composed of three independent cohorts was then performed to verify these blood-based protein biomarkers: the serum discovery and verification cohorts (n = 80; n = 459), and the tissue verification cohort (n = 76). Logistic regression was used to develop a diagnostic biomarker panel. Model validation cohort (n = 160) was used to verify the stability of the constructed predictive model. Changes in serum Cathepsin F (CTSF) levels of patients were tracked to monitor the treatment response. Progression-free survival (PFS) and overall survival (OS) were analysed to assess their prognostic relevance. RESULTS: CTSF and Fibulin-1 (FBLN1) levels were specifically upregulated in sera and tissues of patients with NSCLC BM compared with NSCLC without BM and primary brain tumour. The combined diagnostic performance of CTSF and FBLN1 was superior to their individual ones. CTSF serum changes were found to reflect the therapeutic response of patients with NSCLC BM and the trends of progression were detected earlier than the magnetic resonance imaging changes. Elevated expression of CTSF in NSCLC BM tissues was associated with poor PFS, and was found to be an independent prognostic factor. CONCLUSIONS: We report a novel blood-based biomarker panel for early diagnosis, monitoring of therapeutic response, and prognostic evaluation of patients with NSCLC BM. Nature Publishing Group UK 2022-02-25 2022-06-01 /pmc/articles/PMC9174239/ /pubmed/35217799 http://dx.doi.org/10.1038/s41416-022-01744-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Wei, Song
Liu, Wenwen
Xu, Mingxin
Qin, Huamin
Liu, Chang
Zhang, Rui
Zhou, Sihai
Li, Encheng
Liu, Zhiyu
Wang, Qi
Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer
title Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer
title_full Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer
title_fullStr Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer
title_full_unstemmed Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer
title_short Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer
title_sort cathepsin f and fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174239/
https://www.ncbi.nlm.nih.gov/pubmed/35217799
http://dx.doi.org/10.1038/s41416-022-01744-3
work_keys_str_mv AT weisong cathepsinfandfibulin1asnoveldiagnosticbiomarkersforbrainmetastasisofnonsmallcelllungcancer
AT liuwenwen cathepsinfandfibulin1asnoveldiagnosticbiomarkersforbrainmetastasisofnonsmallcelllungcancer
AT xumingxin cathepsinfandfibulin1asnoveldiagnosticbiomarkersforbrainmetastasisofnonsmallcelllungcancer
AT qinhuamin cathepsinfandfibulin1asnoveldiagnosticbiomarkersforbrainmetastasisofnonsmallcelllungcancer
AT liuchang cathepsinfandfibulin1asnoveldiagnosticbiomarkersforbrainmetastasisofnonsmallcelllungcancer
AT zhangrui cathepsinfandfibulin1asnoveldiagnosticbiomarkersforbrainmetastasisofnonsmallcelllungcancer
AT zhousihai cathepsinfandfibulin1asnoveldiagnosticbiomarkersforbrainmetastasisofnonsmallcelllungcancer
AT liencheng cathepsinfandfibulin1asnoveldiagnosticbiomarkersforbrainmetastasisofnonsmallcelllungcancer
AT liuzhiyu cathepsinfandfibulin1asnoveldiagnosticbiomarkersforbrainmetastasisofnonsmallcelllungcancer
AT wangqi cathepsinfandfibulin1asnoveldiagnosticbiomarkersforbrainmetastasisofnonsmallcelllungcancer